Coyne Terrance P., an insider at Royalty Pharma PLC (RPRX), sold 658,324 shares of the company's stock on November 23, 2025. The shares were sold at a price of $37.96 each, totaling approximately $24.99 million. Following this transaction, Coyne retains the same number of shares, maintaining a significant stake in the company.
Insider transactions can provide insight into executive sentiment, but they don't always indicate a negative outlook. Such decisions reflect a variety of personal or financial considerations, including diversification or tax planning. While large sales may attract attention, they should not be viewed in isolation.
Royalty Pharma, headquartered in New York City, engages in the provision of drug development services and collaborates with a range of innovators from academic institutions to global pharmaceutical companies. The company boasts a market capitalization of $22.7 billion and has a P/E ratio of 29.72. It is well-known for its portfolio, which includes royalties on over 35 commercial products, such as Vertex’s Trikafta and Roche’s Evrysdi.
Investors should consider insider transactions as one piece of the puzzle, examining patterns across multiple insiders and time periods to gain a clearer understanding of company sentiment. Upcoming earnings reports are also on the horizon, with estimates for August 4, 2026, projecting an EPS of $1.34 and revenue of $709.5 million.